Clinical Trial Update: Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating switching HIV-infected kidney transplant recipients to Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy). The study has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Renal Transplant Rejection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: HIV Infections, Renal Transplant Rejection | Phase 4 | Status: COMPLETED | Results posted: 2025-08-12